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Abstract: It is now commonly accepted that most of the mammalian genome is transcribed as RNA,
yet less than 2% of such RNA encode for proteins. A majority of transcribed RNA exists as non-
protein-coding RNAs (ncRNAs) with various functions. Because of the lack of sequence homologies
among most ncRNAs species, it is difficult to infer the potential functions of ncRNAs by examining
sequence patterns, such as catalytic domains, as in the case of proteins. Added to the existing
complexity of predicting the functions of the ever-growing number of ncRNAs, increasing evidence
suggests that various enzymes modify ncRNAs (e.g., ADARs, METTL3, and METTL14), which has
opened up a new field of study called epitranscriptomics. Here, we examine the current status of
ncRNA research from the perspective of epitranscriptomics.
Keywords: epitranscriptomics; non-coding RNA; RNA modifications
1. Introduction
Just as DNA and proteins, RNA can be modified by a variety of enzymes. There are
170+ RNA modifications known to date [1,2], which is much higher than DNA and proteins.
Historically, RNA modifications have been studied for those of housekeeping RNAs, such
as ribosomal RNAs (rRNAs) and transfer RNAs (tRNAs) [3–7] and only recently that the
field of RNA modifications (called epitranscriptomics [8]) has been extended to other RNA
molecules, including protein-coding genes, microRNAs (miRNAs) and long non-coding
RNAs (lncRNAs). This expansion of the epitranscriptomic field is the result of the recent
development of high-throughput methods, such as mass spectrometry and next-generation
sequencing (NGS), especially RNA sequencing (RNA-seq) [9–13]. Among many RNA
modifications, the most famous one in recent years is N6-methyladenosine (m6A), which is
reversible methylation of nitrogen-6 position of adenosine (A) [14,15]. This modification fre-
quently occurs in most eukaryotes, especially in the messenger RNAs (mRNAs) [16–19] and
has been shown to increase during organ maturation and development [20–23] especially
in the adult brain [24], cancer pathogenesis, and progression [25,26]. Because of increased
interest in epitrascriptomics, there is an explosion in the number of publications covering
various aspects of cellular processes, organ developments, and disease progressions for
many different RNA modifications, including m6A, RNA editing, and pseudouridylation.
These RNA modifications have contributed significantly to RNA metabolism, including
transcription, splicing, subcellular location, stability, and translation. Thus, in this review,
we will summarize the current status of epitranscriptomics by focusing on the biogen-
esis of lncRNAs and their functions to provide a concise view of epitranscriptomics in
lncRNA biology.
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2. Different Types of RNA Modification Marks Reported for lncRNAs
Like DNA and histones, RNA undergoes epigenetic modifications termed epitranscrip-
tomics, which exploded over the recent years studying 170+ RNA modifications [1,2]. In
this review article, we focus on the following RNA modifications: m6A, N1-methyladenosine
(m1A), adenosine (A) to inosine (I) RNA editing, 5-methylcytidine (m5C), and pseudouri-
dine (Ψ) [27] (Figure 1).
Figure 1. Schematic representations of RNA modifications. ADAR, adenosine (A) to inosine (I)
RNA editing; AlyREF, Aly/REF export factor; ALKBH proteins, alkB homolog; DNMT2, DNA
methyltransferase-like 2; FTO, fat mass and obesity-associated protein; m1A, N1-methyladenosine;
m6A, N6-methyladenosine; m5C, 5-methylcytosine; METTL, methyltransferase-like; NSUN,
NOP2/Sun domain family members; PUS, pseudouridine synthase; RNMT, RNA guanine-7 methyl-
transferase; RPUSD, RNA pseudouridine synthase domain-containing protein; TRM6, transfer RNA
methyltransferase non-catalytic subunit 6; TRM61, transfer RNA methyltransferase catalytic subunit
61; TRMT10, transfer RNA methyltransferase 10; YTHDC, YTH domain-containing; YTHDF, YTH
domain-containing family. Created with BioRender.com accessed on 31 March 2021.
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2.1. m6A Modification
The methylation of adenosine is catalyzed by two writer proteins, methyl transferase
3 and methyl transferase 14 (METTL3 and METTL14), forming m6A methyl transferase
complex (MTC) [28,29]. Moreover, Wilms tumor 1-associated protein (WTAP) acts as an
adaptor protein that recruits other RNAs and proteins to MTC to target multiple RNA
transcripts [30–32]. Recent studies identified other adaptor proteins, such as RNA-binding
motif protein 15 (RBM15). RBM15B interacts with MTC in a WTAP-dependent manner and
represses the lncRNA X-inactive specific transcript (XIST) transcription [33].
Recent studies uncovered methyl transferase 16 (METTL16) as another writer protein
in the MTC. Importantly, crosslinking sites of METTL16 were found in the ACm6AGAGA
motif, which is mainly found in intronic regions. Intriguingly, ACm6AGAGA motif was
associated with spliceosomes [34,35], suggesting subsets of m6A methyltransferases have
diverse functions, and future studies focusing on understanding the role of METTL16 in
alternative splicing is warranted. On the other hand, recent studies underscored demethy-
lases acting as eraser proteins. Two such proteins, fat mass- and obesity-associated protein
(FTO) and alkylation repair homolog protein 5 (ALKBH5), gained much attention recently,
emphasizing the concept that m6A is a reversible and dynamic process [36]. Mechanisti-
cally, FTO oxidizes m6A to unstable intermediates N6-hydroxymethyladenosine (hm6A) or
N6-formyladenosine (f6A), which further hydrolyzes to adenine. In contrast, ALKBH5 re-
moves the adenosine’s methyl group directly [37]. A group of RNA binding proteins (YTH
N6-methyladenosine RNA binding proteins: YTHDF1, YTHDF2, YTHDF3, and YTHDC1)
specifically recognize the methylated adenosine on RNA that participates in RNA stability
or translation (reviewed in [38]). Overall, m6A writers, erasers, and readers participate in a
complex mechanism crucial for lncRNA functions, especially related to pathogenesis and
progression of various diseases, such as those summarized in the following paragraphs
(Table 1).
Just as mRNAs, m6A modification stabilizes lncRNAs to affect their functions. Exam-
ples include metastasis-associated lung adenocarcinoma transcript 1 (MALAT1); one of
the most studied lncRNA that is involved in many disease conditions [39]. Interestingly,
MALAT1 owns multiple m6A sites (A2515, A2577, A2611, and A2720) [40]. The MALAT1
hairpin contains the domain for the binding of heterogeneous nuclear ribonucleoprotein C
(HNRNPC) and m6A methylation site (A2577) [40]. In the presence of m6A mark, methyla-
tion destabilizes hairpin and enhances HNRNPC binding. Recent work demonstrated that
YTHDC1, an m6A reader, recognizes m6A marks on MALAT1, which plays a crucial role in
maintaining the expression of vital oncogenes via reshaping nuclear spots and genomic
binding [41]. Simultaneously, m6A-deficient MALAT1 rescued the metastatic nature of
esophageal cancer cells [41], suggesting the functional role of m6A marks on MALAT1.
As in the case of MALAT1, most of the published studies on the effects of m6A marks
on the functions of lncRNAs are related to cancers. For example, a study investigating
lncRNA expression profile in 502 head and neck squamous cell carcinoma (HNSCC)
patients identified a significantly elevated level of lncRNA activating regulator of DKK1
(LNCAROD) associated with tumor stage and reduced overall survival [42]. Mechanistically,
the m6A modification through m6A writers, METTL3 and METTL14, stabilizes LNCAROD
expression. Then, LNCAROD by forming a ternary complex with heat shock protein family
A (Hsp70) member 1A (HSPA1A) and Y-box binding protein 1 (YBX1) promotes HNSCC
disease progression [42]. In pancreatic cancer, the m6A demethylase.
(Eraser) ALKBH5 inhibits the disease progression by demethylating the lncRNA
KCNK15 and WISP2 antisense RNA 1 (KCNK15-AS1) and increasing the stability of
KCNK15-AS1, while the down-regulation of KCNK15-AS1 inhibited the cell migration
and invasion [43]. Besides m6A writers and erasers, m6A readers also affect the functions
of lncRNAs via m6A marks. For example, the m6A reader, insulin-like growth factor
2 mRNA binding protein 2 (IGF2BP2), regulates the stability of differentiation antagonizing
non-protein coding RNA (DANCR), which is crucial for pancreatic cancer cell growth and
tumorigenesis [44].
Non-coding RNA 2021, 7, 31 4 of 16
Table 1. A non-exhaustive list of m6A modified lncRNAs.
LncRNA m6A Regulator Function References
MALAT1 YTHDC1 Reshapes the composition of nuclear spots and enhances oncogeneexpression. [41]
LNCAROD METTL3 and METTL14 Promotes HNSCC disease progression. [42]
KCNK15-AS1 ALKBH5 Enhances pancreatic cell migration and invasion. [43]
DANCR IGF2BP2 Enhances pancreatic cancer cell growth and tumorigenesis. [44]
PVT1 ALKBH5 Promotes osteosarcoma cell proliferation, migration, and invasion. [45]
GAS5 YTHDF3 Involved in colorectal cancer. [46]
RP11-138 J23.1 METTL3 Progresses colorectal cancer. [47]
FAM225A METTl3 Enhances nasopharyngeal carcinoma cell, proliferation, migration,invasion, and metastasis. [48]
LINC00958 METTl3 Promotes hepatocellular carcinoma. [49]
linc1281 METTl3 Induces mouse embryonic stem cell differentiation. [50]
BDNF-AS METTL3 Increases the risk of AUD. [51]
Olfr29-ps1 METTl3 Promotes immunosuppressive function and differentiation ofmyeloid-derived suppressor cells. [52]
Yes1 associated transcriptional regulator (YAP) has been a critical factor in colorectal
cancer (CRC) progression [53]. Interestingly, a functional link between m6A modification
and lncRNA in YAP signaling and CRC was reported. In this study [46], an m6A reader,
YTHDF3, is a novel target of YAP that can promote the degradation of m6A modified
lncRNA, growth arrest-specific 5 (GAS5), in CRC progression. In regards to m6A modified
lncRNAs, another lncRNA was reported to be involved in CRC. In this study [47], the
lncRNA RP11-138 J23.1 (RP11) was elevated in CRC patients with the disease progression.
RP11 promoted CRC cell proliferation and metastasis ability by suppressing the proteaso-
mal degradation of the transcription factor, zinc finger E-box binding homeobox 1 (ZEB1);
thereby enhancing epithelial to mesenchymal transition. m6A RNA-immunoprecipitation
(RIP) assays revealed an increased association of RP11 to m6A antibody in CRC cells com-
pared to control cells. Further, the overexpression of METTL3 increased RP11 expression
in the CRC cells, suggesting m6A-induced RP11 expression promotes CRC progression
and is likely a potential biomarker and a novel therapeutic target for CRC [47]. The m6A
modifications on lncRNAs can also play a vital role in their binding efficiency to miRNAs
and/or proteins. For example; the significance of lncRNAs in nasopharyngeal carcino-
genesis (NPC) was addressed in a recent study [48]. Using a microarray-based screening
approach, the authors identified a lncRNA, family with sequence similarity 225 member A
(FAM225A), as the most upregulated lncRNA in NPC associated with poor survival in these
patients. FAM225A enhanced cancer cell proliferation, migration, invasion, and metastasis
by sponging miR-590-3p and miR-1275, which activate integrin-β3 and PI3K/AKT cell
survival pathways. The authors identified two RRACU m6A consensus motifs in the last
exon of FAM225A. Subsequent methylated RNA immunoprecipitation (Me-RIP) assay
revealed elevated m6A levels in NPC cell lines (SUNE-1 and HONE-1) compared to control
nasopharyngeal epithelial cell lines (NP69 and N2Tert). Further, METTL3 knockdown
experiments revealed 50% to 60% reduced total FAM225A expression, suggesting the role
of m6A marks on the FAM225A stability in NPC patients [48]. Another well characterized
oncogenic lncRNA is Pvt1 oncogene (PVT1) [54]. A study shows that the expression of
PVT1 was elevated in osteocarcinoma (OS) tissues and significantly associated with clinical
stage, tumor size, and prognosis of OS patients [45]. Mechanistically, m6A demethylase
(eraser), ALKBH5, interacts with PVT1 to prevent its degradation. Long non-coding RNA
00958 (LINC00958) has been shown to be upregulated in gastric, glioma, gynecological,
oral, and pancreatic cancer [49]. However, its role in hepatocellular carcinoma (HCC) was
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unclear. To address this lack of information, a study demonstrated that METTL3-mediated
m6A modification enhanced the stability of LINC00958 [49]. Mechanistically, LINC00958
acts as miRNA sponge against miR-3619-5p to increase the expression of its target gene,
hepatoma-derived growth factor (HDGF), which promotes HCC growth [49]. The func-
tional connection between m6A marks and lncRNAs as miRNA sponges has been shown in
several studies. One such study demonstrated that m6A modification of a rodent-specific
lncRNA, linc1281, acting as miRNA sponge against let-7, induced mouse embryonic stem
cell differentiation [50]. At the same time, mutations or deletion of METTL3 abolished
linc1281 binding to let-7. Another study identified a lncRNA pseudogene, olfactory recep-
tor 29, pseudogene 1 (Olfr29-ps1), was upregulated in myeloid-derived suppressor cells
(MDSCs) upon proinflammatory stress induced by interleukin 6 (IL-6) [52]. Mechanistically,
Olfr29-ps1 sequestered miR-214 to promote immunosuppressive function and differenti-
ation of MDSCs, whereas these effects were abolished with silencing METTL3 [52]. The
above studies highlight that m6A modifications in lncRNAs dictate their binding efficiency
and functions.
Besides their role in various cancers, it is now clear that m6A modifications in lncRNA
involvement in alcohol use disorders (AUD). For instance, it is well known that adolescent
alcohol drinking contributes to developing AUDs in adulthood. In this perspective, an
elegant study was performed to understand a link between m6A and lncRNAs in the
postmortem amygdala of adolescent drinking individuals (subjects who started drinking
alcohol before or at 21 years of age) [51]. The authors observed that reduced m6A modifi-
cation in the lncRNA BDNF antisense RNA (BDNF-AS) results in the increased levels of
BDNF-AS, subsequently repressing brain-derived neurotrophic factor (BDNF) expression,
a critical factor in the central nervous system and increasing the risk of AUDs, indicating
m6A-mediated action on lncRNAs in another disorder [51].
Circular RNAs (circRNA) are covalently circularized RNA loops that are mainly gener-
ated by pre-mRNA splicing (reviewed in [55]). CircRNAs exhibits differential expression in
response to cellular stress events and various human diseases, including cancers and cardio-
vascular and neurodegenerative diseases [55–59]. Owing to their unique circular structure,
they are naturally inaccessible to exonucleases, resulting in their increased half-life. Thus,
circRNAs represent reliable biomarkers to detect various human diseases. How circRNAs
degrade within cells has been an unanswered question. In this regard, a study revealed
P/MRP endonuclease cuts m6A containing circRNAs via recruiting its reader, YTHDF2,
and its adaptor protein, reactive intermediate imine deaminase A homolog (HRSP12 or
RIDA), to degrade circRNAs [60]. Although circRNAs are considered non-coding, except
for a few circRNAs that exhibited peptide/protein-coding ability [61,62], a remarkable
study demonstrated that single nucleotide m6A modification on circRNAs is sufficient to
promote translation via the recruitment of initiation factor initiation factor eukaryotic trans-
lation factor 4 gamma (elF4G2) and m6A reader, YTHDF [63]. A significant proportion of
circRNAs come from open reading frame (ORF) containing protein-coding genes; however,
what drives ORF-circRNA biogenesis was unclear. In this context, a study revealed that
m6A modification in circRNA drives the biogenesis of circRNA with coding potential in
mouse male germ cells [64]. Taken together, future studies are warranted to address the
functions of the circRNA-derived peptides and proteins.
The role of m6A modifications on circRNAs in immune responses has been a focus
of recent research efforts. A study demonstrated how mammalian cells detect foreign
circRNAs and induce innate immunity [65]. In this study, the m6A modifications in endoge-
nous or self circRNAs inhibit innate immunity, while the absence of m6A modifications
in exogenous or foreign circRNAs activates RNA pattern recognition regulation of RIG-I
(retinoic acid-inducible gene I; official gene name, DExD/H-box helicase 58 (DDX58)) to
induce a robust immune response by activating T-cells and antibody production in human
cells [65]. In contrast, another study showed that the transfection of purified circRNAs did
not induce an immune response and, therefore, propose circRNA potential therapeutic
usage without adverse immune reactions [66]. Taken together, the role of circRNAs in
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the immune-stimulatory function needs further investigation, especially addressing how
endogenous circRNAs achieve self-tolerance and how m6A or other RNA modifications on
circRNAs contribute to inflammation in endogenous vs. foreign circRNAs.
In summary, with the ongoing research on lncRNAs and m6A modification, it has
become evident that m6A modifications regulate multiple biological functions, especially
in various cancers. Future research needs to address the role of m6A modifications on
lncRNAs in other human diseases. Furthermore, m6A modifications on circRNA sequences
and their functional relevance in health and disease need to be thoroughly explored.
2.2. m1A Modification
m1A forms by introducing a methyl group to the N1 position of adenosine. It is not
as abundant as m6A. Unlike m6A, m1A writers include TRMT6, TRMT61A, TRMT10C;
readers for m1A sites include YTHDF1, YTHDF2, YTHDF3, and YTHDC1, which are
mainly similar to m6A. An exciting aspect of m1A is its erasers, ALKBH3 and ALKBH1,
which ensure demethylation of m1A [67–69]. Dysregulation of m1A on tRNA has been
reported in cancers, and an elevated level of ALKBH3 has been reported in pancreatic
cancer [70]. However, how m1A modifications affect lncRNA structures and functions is
still not evident.
2.3. Adenosine (A) to Inosine (I) RNA Editing
Conversion of adenosine (A) to inosine (I) by adenosine deaminase (ADAR) is an-
other prevalent form of RNA modification [71]. Three of these gene family members
were identified in vertebrates [72]. ADAR1 and ADAR2 are expressed in most tissues,
whereas ADAR3 is only expressed in the brain [73]. A-to-I change results in changes in
transcripts and alternative splicing. A-to-I modifications in lncRNAs exhibited cancer pro-
gression and cardiovascular disease [71,74]. Moreover, ADAR1-mediated A-to-I changes in
prostate cancer antigen 3 (PCA3) lncRNA increased its binding with PRUNE2 pre-mRNA
to promote cancer cell proliferation, migration, and invasion [75]. Using hoc indexing and
de novo editing events, a comprehensive inosinome in lncRNAs was performed in the
healthy brain cortex and glioblastoma [76]. The authors identified >10,000 new sites and
335 novel lncRNAs that undergo editing, suggesting the A-to-I RNA editing on lncRNAs
maintains the physiology of healthy brain as well as its dysregulation is linked to tumor
progression [76].
2.4. m5C Modification
m5C is a methylated form of cytosine (C), which is well studied in DNA, tRNA, and
rRNA. Enzymes NOL1/NOP2/SUN domain family member (NSUN) family, NSUN1 to
NSUN7, and DNA methyltransferase-like 2 (DNMT2) have been reported to participate
in this RNA modification [77]. A recent study using modified RNA bisulfite sequencing
identified m5C sites on lncRNAs in HeLa cells, with a low stoichiometry [78]. An elegant
study has shown that methylated cytosine sites in the functional domain of the lncRNA
HOTAIR and XIST are essential for binding to chromatin-associated protein complexes [79].
Furthermore, another study identified comprehensive methylated cytosine in the epitran-
scriptome of the mouse brain and embryonic stem cells in ncRNAs as well, although low
in number [80]. These findings highlight the role of cytosine methylation modifications on
lncRNAs. This is encouraging, and future studies on m5C modification on lncRNAs would
help us better understand their biological and functional role in health and disease.
2.5. Ψ Modificatio
Ψ is known as the “fifth nucleotide” due to its abundance and represents the most
prevalent RNA modifications. Pseudouridine is an isomer of nucleoside uridine catalyzed
by Ψ synthase (PUS) that removes nitrogen-carbon glycosidic bond and replaces its carbon-
carbon glycosidic bond [81]. The presence of 170 Ψ sites was recently identified in lncRNAs;
interestingly, in well-characterized lncRNAs, including MALAT1, XIST, and KCNQ1 oppo-
Non-coding RNA 2021, 7, 31 7 of 16
site strand/antisense transcript 1 (KCNQ1OT1) [82,83]. Thus, future studies are warranted
to uncover functional and mechanistic insights of Ψ in lncRNAs in the context of health
and disease.
3. Impact of Epitranscriptomic Marks on lncRNA Structures
When the first draft of the human genome was introduced, there were high hopes for
understanding many of nature’s rules about the human body. Two decades later, we have
realized that there is more to human genes than simply looking at DNA sequences. The
same situation applies to elucidating the functions of lncRNAs. Many researchers were
excited to read about terminal differentiation-induced non-coding RNA (TINCR) as the
authors identified TINCR box motifs, which are 25-nt long RNA sequences that interact
with many other mRNAs [84]. The discovery of TINCR box motifs prompted a further
search for similar binding domains of other lncRNAs. However, such screening did not
yield fruitful results [85,86]. Not only was such search not successful, but it also recently
became clear that TINCR owns an evolutionary conserved open reading frame, which
encodes for peptides of 87 amino acids [87]. Within this TINCR peptide, one of 10 TINCR
box motifs is included, suggesting that sequence alone cannot be used to infer functions of
lncRNAs. There are a number of methods proposed and used to predict the functions of
lncRNAs by combining different features of lncRNAs, including evolutionary-conserved
sequence motifs, secondary structures, and potential binding of RNA-binding proteins and
miRNAs [85,86,88,89]. Yet, none of such methods can predict the functions of all lncRNAs,
which is not surprising as not all protein-coding genes have been functionally characterized.
In addition to the current challenges facing the computational functional predictions of
lncRNAs, growing evidence of epitranscriptomic marks on lncRNAs is of particular interest
as yet another parameter that researchers need to consider when investigating the functions
of lncRNAs and other types of RNA species.
More than half of the human genome is made up of repetitive sequences [90]. The
Ensembl database currently classifies these repeat sequences into 10 classes (centromere,
low complexity regions, RNA repeats, satellite repeats, simple repeats, tandem repeats,
LTRs (long tandem repeats), SINE (short interspersed nuclear element), LINE (long in-
terspersed nuclear element), and Type II transposons) and categorize those that cannot
be classified into above 10 classes as “Unknown” (https://m.ensembl.org/info/genome/
genebuild/assembly_repeats.html accessed on 22 March 2021). Not surprisingly, such
repetitive sequences are also present in lncRNAs [91–93]. For example, the subfamily of
SINE, Alu elements, can be found in 11% of the human genome [94]. These 300-nt repetitive
repeats are derived from transposons and exist only in primates. These elements can be
expressed as their own RNA [95] or parts of other transcripts (e.g., introns of mRNAs,
lncRNAs), where their expression levels increase upon stresses (e.g., heat shock, hypoxia,
viral infection) [96,97]. When two Alu elements in opposite directions meet, they form
double-stranded RNA, which can be recognized by RNA-binding proteins, such as ADARs.
The ADAR-mediated A-to-I changes also occur frequently in lncRNAs [98–100]. Not sur-
prisingly, these A-to-I conversions change the secondary structures of RNA [101], which
is also an important point to be considered when analyzing for lncRNA functions as the
binding of other macromolecules (i.e., DNA, RNA, and proteins) can alter depending on
the presence (or absence) of double-stranded RNA motifs within a lncRNA [102–104].
Besides A-to-I RNA editing, other epitranscriptomic marks affect the structures of
lncRNAs. In particular, m6A marks are of interest as it has been shown to be in a negative
relationship with A-to-I RNA editing [105]. More recently study shows that silencing of
the m6A writer, METTL3, in glioma stem-like cells altered A-to-I and C-to-U RNA editing
(another type of RNA editing, which is less frequent than A-to-I) events by differentially
regulating RNA editing enzymes ADAR and APOBEC3A, respectively [106]. An interesting
model is proposed recently regarding m6A marks affecting the secondary structure of
one of the most well studied lncRNA, MALAT1 [107]. By performing secondary data
analyses of dimethyl sulfate-sequencing (DMS-Seq) data from human erythroleukemic
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cell line K562 and psoralen analysis of RNA interactions and structure (PARIS) data from
cervical cancer-derived HeLa cells compared to the working structural model of MALAT1 in
noncancerous cells, the authors postulated that m6A-based structural changes of MALAT1
might mediate cancer in a cell-type-specific manner [107]. Thus, increasing evidence
suggests that examining epitranscriptomic marks on lncRNAs is important to uncover the
potential functions of lncRNAs [108].
4. Secondary Analysis of RNA-Seq and m6A-Seq Data to Reveal the Impact of m6A
Marks on lncRNAs
As stated earlier, the most well-studied epitranscriptomic marks in recent years are
m6A. Indeed, a number of lncRNAs have been shown to own m6A marks, including
lincRNA 1281 (official gene name; ephemeron, early developmental lncRNA (Eprn)) during
the differentiation of mouse embryonic stem cells [50], MALAT1 in obstructive nephropa-
thy [109], Pvt1 in sustaining stemness of epidermal progenitor cells [110], and XIST in tran-
scriptional repression [33]. Many more m6A-marked lncRNAs are found in cancers, such
as FOXF1 adjacent non-coding developmental regulatory RNA (FENDDR) in endometrioid
endometrial carcinoma [111], KCNK15 and WISP2 antisense RNA 1 (KCNK15-AS1) in
pancreatic cancer [43], nuclear paraspeckle assembly transcript 1 (NEAT1) in the colon [112]
and gastric cancer [113], as well as miRNA sponges, including long intergenic non-protein
coding RNA 857 (LINC00857) in pancreatic cancer [114], long intergenic non-protein coding
RNA 958 (LINC00958) in breast cancer [115], and PVT1 in osteosarcoma [45]. Further-
more, there are several high-throughput screening studies reporting m6A marks in lncR-
NAs [16,24,116–119] as well as databases (CVm6A [120], DRUM [121], m6A-Atlas [122],
m6Acorr [123], M6A2Target [124], m6AVar [125], MeT-DB [126,127], REPIC [128], RM-
Base [129,130], RMDisease [131], RMVar [132], and RNAWRE [133]) have been released
with m6A marks (and also other epigenetic marks, such as m1A, m5C, RNA editing, and Ψ,
for some databases) in protein-coding and lncRNAs. These screenings are the results of
RNA immunoprecipitation (RIP) using anti-m6A antibody (often termed as m6A-seq) [18]
as well as more elaborate techniques, such as amplicon sequencing evaluation method for
RNA m6A sites after chemical deamination (NOseq) [134], MeRIP-seq (methylated RNA
immunoprecipitation sequencing) [24], and miCLIP (m6A individual-nucleotide-resolution
cross-linking and immunoprecipitation) [118] technologies. As there are several enzymes
involved in m6A (writers, readers, and erasers), in some screening studies, knockdown
of each m6A enzyme was performed to record the dependency of m6A marks for each
enzyme. Yet, most of these studies mainly focus on protein-coding genes as further biologi-
cal validation experiments are possible by examining protein expressions of m6A-marked
transcripts that encode. Furthermore, it is not clear whether m6A-dependent (based on
m6A marks) and -independent effects of m6A enzymes (changes in gene expressions due to
the loss of a particular m6A enzyme but not affecting m6A marks) in such screening studies.
We performed a secondary analysis of previously published RNA-seq data to address
the above point directly. In the original study [135], the authors report that METTL14 is a
crucial component for the crosstalk between histone H3 trimethylation at Lys36 (H3K36me3,
a marker for pre-mRNA splicing) and m6A marks. Using the human hepatoma cell
line HepG2, RNA-seq and m6A-seq experiments were performed upon silencing of m6A
writers—METTL3, METTL14, and WTAP (Gene Expression Omnibus (GEO) accession
GSE110320). Since the original study analyzed only for protein-coding genes and used the
older version of the genome, hg19, a secondary analysis of this data set was performed
using the latest annotation provided by the Ensembl database (GRCh38.103). The usage of
the latest annotation of the human genome is crucial as the number of lncRNAs has been
increased drastically in recent years, which allows us to examine the lncRNAs more care-
fully. Of 19,796 protein-coding and 16,593 lncRNA genes without readthrough transcripts
registered under the GRCh38.103 annotation file, there are less than 100 differentially
expressed genes (both protein-coding and lncRNA genes) upon silencing of each m6A
writer compared to the control (HepG2 cells treated with short hairpin RNA (shRNA)
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against non-specific sequences) (Figure 2A,B, Supplementary Tables S1–S3. When up-and
down-regulated protein-coding genes are compared among silencing of m6A writers, only
two protein-coding genes (HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2) and
LGALS2 (galectin 2)) are shared between silencing of METTL3 and METTL14, while three
protein-coding genes (BHMT (betaine–homocysteine S-methyltransferase), CYP4F2 (cy-
tochrome P450 family 4 subfamily F member 2), and STMN4 (stathmin 4)) are shared
between silencing of METTL3 and WTAP. However, no protein-coding gene is shared
among all three conditions (Figure 2C). In the case of down-regulated protein-coding genes,
no gene was shared (Figure 2D). Unlike the protein-coding genes, only 11 non-overlapping
lncRNA genes are identified as up-regulated (Figure 2E). Simultaneously, there is no down-
regulated lncRNA gene in the silencing of any of three m6A writers compared to the control,
suggesting that at the level of transcriptional control, m6A writers influence different sets of
protein-coding genes. However, such transcriptional influence is rather minimal, especially
since such transcriptional control via m6A writers is negligible for lncRNA genes, even for
the mRNA-seq (targeting only RNA with poly A tails; thus missing about half of lncRNAs
without poly A tails).
Figure 2. RNA-seq data of silencing of m6A writers in HepG2 cells. (A) volcano plots comparing
silencing of METTL3, METTL14, or WTAP to the control sample group. With the threshold values of
2-fold and FDR-adjusted p < 0.05, protein-coding genes are colored in red, lncRNA genes in blue, and
other genes (e.g., pseudogenes) in yellow-green. (B) the table indicates the number of differentially
expressed genes for each category. (C,D) Venn diagrams for shared protein-coding genes that are
(C) up- and (D) down-regulated in each condition. (E) heatmaps of target m6A reader genes followed
by up-regulated lncRNA genes in each condition.
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5. Materials and Methods
5.1. RNA-Seq Data Analysis
RNA-seq data were downloaded from the Sequence Read Archive (SRA) database
using SRA Toolkit. [136] FASTQ files were preprocessed with fastp [137] (version 0.21.0)
using the default setting. After preprocessing of sequencing reads, STAR [138] (version
020201) was used to map the reads to the reference genome (GRCh38.103). To calculate
counts per million (CPM) values and derive differentially expressed genes, the R package,
edgeR [139] (version 3.30.3), was used. False discovery rate (FDR)-adjusted p-values were
used for further analysis.
5.2. Data Analysis and Visualization
Volcano plots were generated using R-package, ggplot2 [140]. To draw heat maps,
MultiExperiment Viewer (MeV) [141] was used.
6. Conclusions
On the whole, we summarize updates on lncRNA epitranscriptomics, in the context of
lncRNA function and biology. Even though the last couple of decades of research revealed
the importance of epitranscriptomics in health and disease, several questions still need to
be answered, such as future insights into the functional importance of RNA modification in
lncRNAs? Are these modifications conserved between species, whether these modifications
are mediators or actual drivers? How do we identify different modifications on the same
lncRNA? Can these modifications be targeted to restrict disease progression? All these
above questions would unravel our understanding of epitranscriptomics as novel disease
mechanisms to design effective and targeted therapeutics.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ncrna7020031/s1, Table S1: Differentially expressed genes in silencing of METTL3 (shMETTL3)
compared to the control; Table S2: Differentially expressed genes in silencing of METTL14 (shMETTL14)
compared to the control; Table S3: Differentially expressed genes in silencing of WTAP (shWTAP)
compared to the control.
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